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1. Introduction
1.1. Leishmaniasis
Leishmaniasis is a vector-born disease caused by protozoan parasites in the genus Leishma‐
nia. Leishmaniasis is a potentially lethal, neglected disease that mostly affects economically
disadvantaged individuals in many developing countries. Human infection occurs through
the bite of infected female phlebotomine sand flies followed by injection of promastigote forms
into the skin, which penetrate the macrophages and/or other types of mononuclear phagocytic
cells. The promastigotes then transform into amastigotes (tissue stage of the parasite) in these
cells and replicate, resulting in the bursting of the host cell and infection of other mononuclear
phagocytic cells. Sand flies become infected by ingesting amastigote-infected cells during
blood meals. These evolutionary forms transform into promastigotes in the gut of the insect
and migrate to the proboscis, infecting other people through the bite (Scheme 1).
Depending on the Leishmania species involved and the host immune response, infection can
lead to tegumentary or visceral manifestations of the disease. The tegumentary form of
leishmaniasis (TL) includes cutaneous (CL), mucocutaneous (MCL), and diffuse (DL) clinical
manifestations. All tegumentary forms have a major impact on patient life, because the skin
lesions can lead to disfigurement and social stigmatization [2, 3]. Visceral leishmaniasis (VL),
or Kala-azar, affects organs and internal tissues such as spleen, liver, bone marrow, and lymph
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nodes. With the progression of VL, splenomegaly and hepatomegaly lead to a distended
abdomen and pain. Eventually, VL may lead to death caused by secondary infections, severe
anemia, or organ failure [4]. Both TL and VL are endemic diseases in several countries. In fact,
the number of cases of leishmaniasis may be underestimated because only 40 of the 88 countries
where the disease frequently occurs report cases on a regular basis [5, 6].
The World Health Organization (WHO) estimates that 1.6 million new leishmaniasis cases
occur annually, of which 500,000 correspond to VL (90% of them occurring in Bangladesh,
Brazil, Ethiopia, India, Nepal, and Sudan) and 1.1 million to CL (90% of them occurring in
Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia, Sudan, and Syria) [7]. Leishmaniasis
currently affects an estimated 12 million people and approximately 350 million people live at
risk of infection [1], whereas an estimated half a million people die annually of VL. In addition,
Scheme 1. Leishmaniasis life cycle. 1- sand flies inject promastigotes during blood meals ;2-promastigote infects mac‐
rophages and other types of mononuclear phagocytic cells;3-promastigotes transform into amastigotes; 4-amasti‐
gotes multiply. 5- sand flies become infected by ingesting macrophages infected with amastigotes during blood
meals; 6- parasitized cells ; 7- in sand flies, amastigotes transform into promastigotes, in the gut; 8- promastigotes di‐
vide and migrate to proboscis based on CDC, 2013 [1].
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immunosuppressive conditions such as AIDS contribute to the emergence of severe clinical
forms of the disease. To date, the greatest prevalence of Leishmania-HIV co-infection has been
reported in the Mediterranean basin [8, 9]. In some east African regions, up to 40% of patients
with VL are co-infected with HIV, which further complicates treatment [10].
2. Current drugs
Currently, most antileishmanial drugs can be considered orphan drugs. In fact, leishmania‐
sis, Chagas disease, are examples of tropical neglected diseases (TND) as they receive little
attention from governments and the pharmaceutical industry. For instance, by the 2000s,
global investment in new anti-parasitic drugs was only about 0.1% of global investment in
research  [11,  12].  Additionally,  the  lack  of  human  vaccines  for  leishmaniasis  makes
chemotherapy the primary method used to control  the disease.  Despite  the existence of
several  chemotherapics  to  treat  human  leishmaniasis,  many  of  them  are  new  formula‐
tions of ancient drugs [13]. The chemotherapeutic agents currently used in the treatment
of  VL  and  TL  such  as  stibogluconate  of  sodium  (Pentostam®),  N-methylglucantime
(Glucantime®),  pentamidine  (Pentacarinato®),  and  amphotericin  B  (Fungizone®)  do  not
possess activity when orally administered and require parenteral administration for long
periods  [14].  In  addition,  those  chemotherapeutic  agents  are  very  expensive  and  cause
severe side effects due to their high toxicity [15].
Taken together, all these factors contribute to poor patient adherence or abandonment of
treatment. In turn, treatment failure has a great impact on the spread of the disease and
the emergence of drug-resistant strains. However, the introduction of new chemotherapeu‐
tic agents, including liposomal amphotericin B (AmBisome®),  paramomycin, and miltefo‐
sin  has  certainly  improved  the  current  scenario  for  the  treatment  of  leishmaniasis.
AmBisome®  has  become  the  first-choice  drug  for  treating  VL  in  several  countries.  For
instance, this treatment is currently used in Bihar, India, because pentavalent antimonials
have become less effective against parasites [16, 17]. However, none of these drugs are free
of severe side effects and the development of new strategies and/or alternative therapeu‐
tic agents remain crucial.
The  incorporation  of  amphotericin  B  into  lipid  formulations  has  brought  new  perspec‐
tives to the treatment of leishmaniasis, resulting in the incorporation of several other drugs
to different  lipid formulations,  including meglumine antimoniate [18],  furazolidone [19],
paromomycin sulfate [20] and miltefosin [21]. Conventional chemotherapeutics usually have
difficulty reaching target tissues in therapeutic concentrations and are also associated with
toxic effects on healthy organs and tissues. Thus, drug delivery approaches should improve
the  efficacy,  specificity,  tolerability,  and  therapeutic  index  of  antiparasitic  agents  [12].
However,  despite advances in the efficacy of  existing drugs,  the toxic potential  of  these
substances  must  be  considered.  Thus,  the  search  for  new  strategies  and/or  alternative
therapeutic agents is crucial.
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3. Natural products and drug delivery systems against leishmaniasis: state-
of-the-art
The use  of  tools  and materials  at  the  nanoscale  enabled the  creation of  nanoparticulate
formulations such as liposomes, microemulsions, and microcapsules of great interest to the
pharmaceutical industry. Drug delivery systems using liposomes are the ones most studied
because of their high biocompatibility,  ease of preparation, and chemical versatility [22].
Basically, liposomes are microscopic vesicles composed of one or more concentric lipid bilayers
separated by aqueous media. Liposomes can encapsulate hydrophilic and lipophilic substan‐
ces; the former stay in the aqueous compartment, whereas the latter are inserted into the
membrane. Because liposomes are biodegradable, biocompatible, and non-immunogenic, they
are highly versatile for research, therapeutic, and analytical applications [23]. These vesicles are
primarily consisted of phospholipids (either synthetic or natural), sterols, and antioxidants [24].
Lipids with a cylindrical shape such as phosphatidylcholine, phosphatidylserine, phosphatidyl‐
glycerol, and sphingomyelin, which tend to form a stable bilayer in aqueous solution, are
commonly used in liposomal formulations. Phosphatidylcholine is the most employed lipid in
liposomal  formulation studies  due to  its  great  stability  against  pH or  salt  concentration
variations in the medium [25]. The pharmacokinetic properties of liposomes can be simply
modified by changing the chemical composition of the bilayer components. Moreover, peptides,
polysaccharides, or affinity ligands such as antibodies can be incorporated into liposomes [12].
Phospholipid-based liposomes are usually used to change the pharmacokinetics profile of
several drugs, either natural or synthetic ones. Natural products such as crude extracts, fractions,
or isolated phytocompounds have been incorporated into different colloidal carriers, includ‐
ing liposomes, with promising results. As expected in the incorporation of synthetic drugs, lipid
formulations enhance the solubility and bioavailability of extracts and bioactive compounds
derived from plants. Additional benefits of phytoformulations include: (i) protection from
toxicity; (ii) enhanced pharmacological activity; (iii) enhanced stability; (iv) increased reten‐
tion time; and (v) protection from physical and chemical degradation [26,22]. The ability of
colloidal carriers to improve tissue macrophages distribution may have an impact on Leishma‐
nia infection. The tendency of nanoformulations, especially liposomes, to be captured by the
mononuclear phagocyte system may be an additional advantage in the treatment of leishmania‐
sis. In fact, intraperitoneal and intravenous administration of liposomes proved to be a good
biodistribution system for drugs in the treatment of VL, because it increased drug accumula‐
tion in macrophage-rich tissues such as liver and spleen, thus reducing the toxicity level to other
tissues and organs [27].
Since ancient times, products from plant, mineral, and animal sources have been used in
traditional medicine to fight many human diseases. In fact, for centuries traditional medicine
has been the only health care system available for the prevention and treatment of several
diseases in different cultures. Currently, the practice of traditional medicine still has a great
impact on the health of people who have no access to modern health care practices. In fact, an
estimated 80% of people living in developing countries rely almost completely on traditional
medicinal practices to meet their primary medication needs [28-30]. Thus, the use of natural
products as medicines has attracted the interest of research laboratories around the world
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seeking new bioactive molecules. Among the most studied natural products, plants are a
valuable source of compounds with antileishmanial activity. Active compounds derived from
plant extracts have been described by several laboratories worldwide [31-34]. The antileishma‐
nial activity of several crude extracts and fractions derived from plants has been attributed to
compounds  belonging  to  diverse  chemical  groups,  including  phenolic  compounds  (e.g.,
chalcones, flavonols, aurones, lignans, coumarins, quinines, tannins), terpenoids (monoter‐
penes, sesquiterpenes, diterpenoids, triterpenes), and alkaloids (indole alkaloids, isoquino‐
line alkaloids, quinoline alkaloids) [35-37]. In fact, phytoscience may be an important tool in the
search for novel antileishmanial agents with fewer side effects and lower potential costs.
Secondary metabolites isolated from plant extracts or essential oils can be used in several
different ways for the development of drugs. Nanoformulation-based delivery systems are a
promising approach to developing novel antileishmanial agents.
Species Family Geographical origin(country) Part used References
Aesculus
hippocastanum Hipocastanaceae not cited Seeds [40]
Andrographis
paniculata Acanthaceae (India) Leaves [41, 42]
Bacopa monniera Scrophulariaceae(Plantaginaceae) (India) Leaves [43, 44]
Camptotheca
acuminata Cornaceae (China) bark, stem [45]
Curcuma longa Zingiberaceae (India) rhizome [46]
Fagopyrum
esculentum Polygonaceae (India) not cited [39, 47]
Mimusops elangii Sapotaceae (India) Seeds [48]
Peganum harmala Nitrariaceae (India) Seeds [49, 50]
Piper aduncum Piperaceae (Brazil) inflorescence [51]
Piper nigrum Piperaceae (India) Seeds [52, 53]
Swertia chirata Gentianaceae Himalayan region(India) aerial part [54, 55]
Taxus baccata Taxaceae Peloponnese region(Greece)
needles,
branches [56]
Terminalia bellerica Combretaceae — stem bark [57]
Zanthoxylum
chiloperone Rutaceae Cordillera (Paraguay) stem bark [58, 59]
Table 1. Natural sources of active substances used in nanoformulations against Leishmania.
Table 1 lists the natural sources used in nanoformulations to improve the bioavailability of
antileishmanial  drugs,  thus  increasing  their  expected  therapeutic  efficacy.  However,  the
botanical species used for isolation of the active constituent have not been described in some
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formulations such as those containing asiaticoside and acaciaside [38], whereas others have a
plant origin but were purchased commercially [39]. It should be noted that the most studied
species listed in Table 1 are native to developing countries, where the popular use of medici‐
nal plants is widespread.
4. Phytocompound nanoformulations and antileishmanial activity
In the last decades, advances in nanoscience have enabled the development of nano-range
materials approved for therapeutic use or in clinical development stage. In fact, many
encapsulation matrices have been approved by the Food and Drug Administration (FDA) for
use in humans, i.e., a wide range of naturally or chemically modified cyclodextrins that are
extensively used in medicine and food fields [60, 61]. Similarly, vesicular systems such as
liposomes, niosomes, nanoparticles, and microspheres are very useful and have many
advantages in delivering drugs of natural origin, representing a promising approach for the
treatment of several diseases, including leishmaniasis. Nanoformulations prepared with
compounds from medicinal plants and their antileishmanial activity are summarized in Table
2. Liposomes, niosomes, and nanoparticles are the main formulations investigated.
Saponins (liposomes) and alkaloids (nanoparticles) are among the main plant constituents
used to prepare nanoformulations. Liposomes are mainly formed by a mixture of phosphatidyl
choline (PC), cholesterol (Chol), and phosphatidic acid (PA), usually in a 7:4:1 molar ratio [55,
38], whereas nanoparticle formulations have polylactide (PLA) as their main ingredient,
providing greater stability, biocompatibility, and an efficient delivery system compared to
liposomal structures [50, 57]. The antileishmanial properties of each nanoformulation are
briefly cited below.
Flavonoids are among the most common phenolic compounds found in the human diet and
a variety of members of this family has been described as bioactive agents. Significant
antiprotozoal activity of flavonoids has been reported against Trypanosoma and Leishmania
species. Quercetin (Fig. 1) is a widely studied food-derived flavonoid with several biological
effects, including antioxidant, antihypertensive, anti-inflammatory, and antiprotozoal
activities. Quercetin inhibits parasite arginase activity [62,63] and induces the production of
superoxide anion, hydrogen peroxide, and other reactive oxygen species (ROS) by infected
cells. Thus, ROS generation induced by quercetin could be crucial for maximal antiparasitic
activity, because ROS are naturally generated by macrophages as a mechanism to kill intra‐
cellular parasites such as Leishmania [64, 65]. In fact, liposomal, niosomal, microspherulated,
and nanocapsulated quercetin formulations have been tested to evaluate the best drug delivery
system. In hamster models of L. donovani infection, all quercetin vesicular formulations
reduced the parasite load compared to the free form of the drug. Nanocapsulated quercetin is
more effective than non-capsulated quercetin in the control of leishmaniasis (87% reduction
in spleen parasite burden) and its pronounced activity may be related to vesicular composition
and size. Moreover, drug efficacy may be inversely correlated to the size of vesicular forms [39].
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Similarly, the incorporation of terpenoids into nanoparticle carriers has also shown promising
results. The search for active molecules to treat leishmaniasis is very laborious, because most
molecules have low solubility. The incorporation of andrographolide (Fig. 2), a diterpenoid
extracted from the herbaceous species Andrographis paniculata (Acanthaceae), with different
poly (d,l-lactide-co-glycolide) (PLGA) nanoformulations enhanced the antileishmanial
activity of andrographolide against axenic and intracellular amastigote forms of L. donovani.
Among the formulations tested, the 175 nm andrographolide-loaded nanoparticles exhibited
the best antileishmanial activity (IC50 = 36 and 28µM for axenic and intracellular amastigotes,
respectively) [66]. Andrographis paniculata can be considered an interesting source of antileish‐
manial agents. While 14-deoxy-11-oxoandrographolide (Fig. 2), an andrographolide-derived
diterpenoid, reduced spleen parasite load in hamster models of L. donovani infection in 39%,
liposomal, niosomal, and microspherulated formulations of this substance suppressed spleen
parasite load by 78, 91, and 59%, respectively. In addition, the toxicity of 14-deoxy-11-
oxoandrographolide to hepatic tissue also decreased after incorporation of 14-deoxy-11-
oxoandrographolide into colloidal carriers, as demonstrated by the normal levels of serum
alkaline phosphatase (ALP) and serum glutamate pyruvate transaminase (SGPT) in the blood
[67]. Interestingly, particle size also proved to be an important factor for drug delivery efficacy.
In fact, nanoparticles in a size range below 200 nm have been associated with increased
phagocytosis by Leishmania-infected macrophages [68].
Formulations Active ingredients AdministrationRoute
Target and
Parasite reduction
% Entrapment
efficiency References
Liposomes
Niosomes Amarogentin SC
L. donovani
(LP 69% and NS 90%)
33
24 [55]
Mannose-coated
Liposomes
Liposomes
Piperine SC L. donovani(ML 90%; LP 77%) 22 [52]
Nanoparticles 2
’,6’-dihydroxy-4’-
methoxychalcone IP
L. amazonensis
(53%) 92 [51]
Liposomes camptothecin IP L. donovani(55%) 2.7 [45]
Liposomes
Niosomes
Micropspheres
Nanoparticles
Quercetin SC
L. donovani
(LP 51%; NS 68%; MS 44%;
NP 87%)
40
50
09
-
[39]
Liposomes
Niosomes
Nanoparticles
Microspheres
bacopasaponin C SC
L. donovani
(LP 81%; NS 86%; NP 79%;
MS 91%)
30
30
30
50
[44]
Liposomes
Niosomes
Micropspheres
14-deoxi-11-
oxoandrographolide SC
L. donovani
(LP 78%; NS 91%; MS 59%)
10
1
10
[42]
Liposomes Harmine SC L. donovani 65 [50]
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Formulations Active ingredients AdministrationRoute
Target and
Parasite reduction
% Entrapment
efficiency References
Niosomes
Nanoparticles (LP 60%; NI 70%; NP 80%)
60
20
Lipid nanospheres Piperine IV L. donovani(52-90%) 100 [53]
Liposomes asiaticoside nr L. donovani(LP 62%) Nd [38]
Liposomes acaciaside nr L. donovani(LP 92%) Nd
Microemulsion
Nanoparticles bassic acid SC
L. donovani
(ME 62%; NP 78%)
100
50 [48]
Nanogels
Nanoparticles arjunglucoside I SC
L. donovani
(NG 79%; NP75%)
80
60 [57]
Nanoparticles andrographolide in vitro assay
L. donovani
Axenic amastigotes
(IC50 = 36 ± 4 μM/mL)
Amastigotes in macrophage
(IC50 = 28 ± 2 μM/mL)
80 [66]
Nanoparticles β-aescin in vitro assay
L. infantum
Amastigotes (IC50 = 1.04
± 0.23ug/ml)
2.8 – 31.9 [40]
Gold nanoparticles quercetin in vitro assay
L. donovani
Axenic amastigotes
(IC50 = 15 ± 3 μM/ml)
Amastigotes in macrophage
(IC50 10 ± 2 μM/ml)
77 [69]
LP: liposomes; NS: niosomes; ML: manose-coated liposomes; NP: nanoparticles; MS: microspheres; ME: microemulsions; NG:
nanogels.
SC: subcutaneous; IP: intraperitoneal; IV: intravenous.
nr: not reported; nd: not determined.
Table 2. Phytocompound nanoformulations and antileishmanial activity.
Triterpenoidic or steroidal saponins directly reduce cell viability via membrane disruption.
The mode of action of saponins is related to its aglycone portion, which binds to membrane
sterols, leading to the formation of transmembrane pores and loss of intracellular content. This
feature of saponins demonstrates the toxic potential of these molecules, hampering their use
as antileishmanial agents. Conversely, polymeric nanoparticles composed of PLGA were
successfully used to improve the efficacy of β-aescin (Fig. 2), the main saponin isolated from
the seeds of horse-chestnut Aesculus hippocastanumi (Sapindaceae), lowering its cytotoxic effect
for mammalian cells [40]. Bacopasaponin-C (Fig. 2) was firstly reported as an antileishmanial
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agent in 2002, but its mechanism of action remains unclear. This glycoside extracted from
Bacopa monnieri (Plantaginaceae) has glucose and rhamnose residues attached to the triterpe‐
noid aglycone moiety. The glucose residue may be responsible for targeting bacopasaponin-
C to glucose receptors on the cellular surface. Incorporation of bacopasaponin-C into various
delivery carriers (niosomes, microspheres, nanoparticles, and liposomes) improved its
antileishmanial activity. After six-day treatment with subcutaneous injections of liposomal,
niosomal, microencapsulated, or nanocapsulated formulations of bacopasaponin-C, hamster
models of L. donovani infection showed a significant reduction in spleen parasite burden (81,
86, 79, and 91%, respectively) compared to free drug-treated animals (40%). At the same dose
(1.7 mg/kg), the smallest vesicles had the best efficacy, as follows: nanocapsules > niosomes >
liposomes > microspheres [44]. Another glycoside with remarkable activity against Leishma‐
nia parasites has been isolated from the indigenous plant Swertia chirata (Gentianaceae):
amarogentin (Fig. 2) is a secoiridoid glycoside with the capacity to inhibit DNA-topoisomerase
I, an essential enzyme related to Leishmania viability. Liposomal and niosomal formulations of
amarogentin (2.5 mg/kg) reduced spleen parasite load by 69 and 90%, respectively, whereas
free drug at equivalent dose reduced parasite load by 39%. In addition, both SPTG and ALP
activity remained close to normal levels when liposomal or niosomal formulations of this
iridoid were used in murine models [55].
The amide alkaloid piperine (Fig. 3) extracted from Piper nigrum (Piperaceae), an Indian species
commonly used in traditional medicine, has been reported as a potent antileishmanial acting
against both visceral (L. donovani) and tegumentary (L. amazonensis) leishmaniasis [70, 71]. In
vivo tests have shown that piperine entrapped into liposomes and mannose-coated liposomes
were effective against murine models of L. donovani infection. After 12-day treatment with
liposomal and mannose-coated liposomal formulations of this alkaloid (four doses, 6 mg/mL)
administered subcutaneously, a reduction in parasite burden of approximately 77 and 90%,
respectively was achieved. Free piperine not only was less effective in reducing parasite
burden (29%)but also had higher toxicity to liver compared to the colloidal carriers (ALP = 20.5
µmol of p-nitrophenol released/min/dL of sera and SGPT = 77.2 µmol of sodium pyruvate/min/
L of sera) [52]. Nevertheless, better results can be achieved by using lipid nanospheres of
piperine (LN-P). A single dose (5 mg/kg) of the lipid formulation composed of stearylamine
(LN-P-SA) reduced parasite burden in liver and spleen of L. donovani-infected hamsters by 90%
and 85% after 15 days post infection, respectively. Despite the size of the vesicles (about 884.6
nm), the efficacy of LN-P-SA may be related to the preferential uptake of stearylamine-bearing
Figure 1. Structure of phenolic compounds loaded in nanoformulations.
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Figure 2. Structure of terpenoids loaded in nanoformulations.
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positively charged liposomes (+ 24.2 mV) by peritoneal macrophages compared to neutral and
negatively charged vesicles [53].
β-carboline alkaloids such as harmane, harmaline, and harmine were initially described as
potent psychoactive and hallucinogenic agents. However, a wide range of pharmacological
activities have been reported for those compounds, including those against Leishmania
parasites [72]. Harmine (Fig. 3), isolated from Peganum harmala (Nitrariaceae), displays in
vitro anti-L. donovani promastigote activity at 25 µg/mL. Recently, this alkaloid was incorpo‐
rated into liposomes, niosomes, and nanoparticles at an equivalent dose of 1.5 mg/kg body
weight, and after six doses administered subcutaneously to L. donovani-infected murine
models, all harmine-entrapped vesicular formulations were able to reduce spleen parasite
burden, especially nanosomes (a reduction of about 79%). Nevertheless, the mechanism of
action of harmine against Leishmania remains unclear and may be related to necrotic membrane
damage.
Figure 3. Structure of alkaloids loaded in nanoformulations.
The search for new compounds with antileishmanial activity in medicinal plants is an
interesting strategy, however most studies are still limited to basic research and probably only
a few compounds will reach stages of clinical trials and development of new drugs. The
combination of phytochemistry and nanoformulations may open up new perspectives in the
search for new antileishmanial drugs, because drug delivery systems based on nanoformula‐
tions can improve the effectiveness of natural compounds making them more attractive to the
development of new therapeutic targets. Due to their structural versatility in terms of size,
composition, and ability to incorporate hydrophilic or lipophilic substances, there are many
possible applications of nanoparticulate formulations in the treatment and control of leish‐
maniasis.
5. Parasite targets for new drugs
Parasite resistance, cost, side effects, toxicity, and other therapy issues prompt an urgent need
to identify and develop new drugs and alternative targets for leishmaniasis treatment [73, 74,
10]. Metabolic pathways such as glycolytic pathway [75, 76], polyamine biosynthesis [77, 78],
glyoxalase pathway [79, 80], uptake and turnover of phospholipids/sphingolipids [81, 82],
microtubule biosynthesis [83, 84], and folate metabolism [85] have been targeted.
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The development of drugs directed at new targets such as parasite enzymes represents another
approach in the search for new antileishmanial drugs. Arginase is a recently described target
for the treatment of leishmaniasis. The enzyme is localized in the glycosome, a subcellular
organelle found in some trpypanosomatids such as Leishmania. Inhibition of the arginase
pathway causes inhibits the polyamine biosynthetic pathway, resulting in antileishmanial
activity [86].
Other enzyme systems investigated as potential targets for antileishmanial drug action include
nitric oxide synthase, DNA topoisomerase, trypanothione redutase, superoxide dismutase
enzymes, and hypoxanthine-guanine phosphoribosyltransferase [74]; heme oxygenase-1 [87];
ribose 5-phosphate isomerase B [88]; dihydroorotate dehydrogenase [89]; ornitine decarbox‐
ylases [62]; Abl family kinases and phosphoinositide 3-kinase γ [90-93]; and spermidine
synthase [94, 95].
A total of 154 peptidases were detected in the Leishmania major genome, including serine,
cysteine, aspartic, threonine, and metallopeptidases. The cysteine peptidase-specific inhibitor
K11777 has shown that these peptidases are necessary for parasite growth [96]. Even though
some inhibitors have been developed but failed to kill parasites, peptidases are promising
targets [97-99].
Carbonic anhydrases (CAs, EC 4.2.1.1) are a new target that are starting to be studied for
Leishmania. CAs are metalloenzymes that catalyze CO2 hydration to bicarbonate and protons,
and five CA classes have been identified: α, β, γ, δ, and ζ. The reaction catalyzed by CAs is
essential in the regulation of acid-base balance in organisms [100, 101]. A β-carbonic anhydrase
was recently cloned and characterized from Leishmania donovani chagasi, and enzyme-specific
inhibitors were tested against Leishmania [102].
The death of the parasite by inhibiting an enzyme or pathway essential for parasite survival
and non-essential for the host requires the exploration of differences between these pathways
or enzymes [103]. Thus, new Leishmania molecules should be studied and the possibility of
developing rational and more effective drugs with less harmful side effects for the host
investigated. Finally, new Leishmania chemotherapeutic targets and new approaches to the
development of drugs should be considered [104, 93, 105].
6. Synthetic drugs
No vaccine candidates for leishmaniasis are currently under animal or clinical trials. Thus, new
and effectives drugs should be investigated. In the last years, several drugs have been studied
to find potential new drugs with desirable characteristics. Leishmaniasis is expanding in
developed countries and in North America and Europe, which has alarmed health authorities
worldwide [106]. Although leishmaniasis is treatable, it is difficult to control due to the absence
of an effective vaccine, the adaptation of the vector and reservoir hosts to human environments,
and the emergence of resistant lineages [107]. The first-line chemotherapy drugs available are
pentavalent antimonials [108], whereas pentamidine and amphotericin B are second-line
therapies, but these are associated with limited effectiveness, a long-term treatment, toxicity,
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and significant side effects [109]. Consequently, there is an urgent need to discover new drugs
that are effective against leishmaniasis [110].
Some compounds have been studied and regarded as promising new drugs. The stilbene
trans-3,4',5-trimethoxy-3'-amino-stilbene (TTAS) showed a LD50 of 2.6 lg/mL against Leishma‐
nia infantum with low toxicity. The action mechanism is the disruption of the mitochondrial
membrane potential and the ability to block Leishmania parasites during the G2/M phase of
cell cycle [111].
N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide has been
tested against Leishmania amazonensis and ultrastructural alterations, depolarization of the
mitochondrial membrane with loss of cell membrane integrity, and increased formation of
mitochondrial superoxide anions were detected, indicating that this compound induced
mitochondrial dysfunction [111].
Besides the lack of an effective vaccine against leishmaniasis, in some East African regions, up
to 40% of patients with visceral leishmaniasis are co-infected with HIV, which complicates the
treatment. Peptidase inhibitors, used to treat HIV-infected individuals are a new route that
needs more studies. HIV-1 protease inhibitors such as Indinavir, Saquinavir, and others have
been tested to treat leishmaniasis and inhibition of parasite growth has been reported at high
drugs concentrations [9].
Other synthetic antileishmanial compounds are currently being developed an evaluated for
therapeutic use. β-carbolines from various natural and synthetic sources have shown diverse
biological activities. A total of 22 compounds were synthesized and tested in vitro against
Leishmania donovani, out of which six compounds (4, 5, 10, 11, 19, and 22) showed more activity
than the standard miltefosine (IC50 = 12.07 ± 0.82 lM), with compound 4 being the most potent
(IC50 = 2.16 ± 0.26 lM) [112]. Moreover, a semi-synthetic berberine analogue, 5,6-didehydro-8,8-
diethyl-13-oxodihydroberberine chloride showed nanomolar level potency against in vitro
models of leishmaniasis, malaria, and trypanosomiasis, as well as activity in an in vivo visceral
leishmaniasis model [113]. Tamoxifen is a synthetic estrogen that has been successfully used
to prevent recurrence of breast cancer in women who are estrogen-receptor positive. Miguel
et al. (2008) [114] reported the leishmanicidal activity of tamoxifen in vitro using BALB/c mice
infected with L. amazonensis and treated with this compound for 15 days.
Diospyrin, a bis-naphthoquinone isolate from the tree Diospyros montana and its semi-
syntheitic derivatives showed inhibitory activity against Leishmania spp. The di-epoxide
derivative of diospyrin (D17) was more effective against L. donovani promastigotes than
diospyrin. The same derivative tested in L.donovani BHU1216 selectively inhibited intracellular
amastigotes. Computational docking studies demonstrated that D17 could inhibit L donovani
ornithine decarboxylase but not trypanothione reductase [115].
Therapeutic approaches using drugs that act on structures of vital importance to the parasite
but absent or sufficiently different in their hosts have been explored by several research groups.
Indotecan and AM13-55, are TopIB poisons with indenoisoquinoline structure. Both com‐
pounds were tested against L infantum and the results compared with paromomycin, a
leishmanicidal drug. The tests were done on a murine BALB/c model of splenocytes infected
with L. infantum. The results showed that Indotecam reduced more than 80% of the parasite
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burden of the spleen and liver, indicating that this compound is a potential drug against
visceral leishmaniasis [116].
TiO2@Ag nanoparticles (TiAg-Nps) produce reactive oxygen species (ROS), which have an
antimicrobial effect, including antileishmanial effects on Leishmania tropica and Leishmania
infantum promastigotes and amastigotes, mainly non-visible light-exposed TiAg-Nps [117].
Twenty-four porphyrin precursors and derivatives were evaluated against Trypanosoma
brucei, L. donovani, and Plasmodium sp. The perforine 4i derivative showed the best activity
against T. brucei with a MEC value of 6.25 mM, but the compound was not active against
intramacrophage amastigotes of L. donovani [118].
Another approach used in studies is the combination of drug therapies aimed at finding the
most effective and secure one. Pam3Cys (an in-built immunoadjuvant and TLR2 ligand) and
miltefosine were combined and the resulting combination was evaluated. All experiments
were done in BALB/c mouse. Parasitic inhibition significantly increased in groups treated with
combinations of the drugs compared to groups receiving miltefosine and Pam3Cys separately.
Moreover, increased production of Th1 cytokines, RNS, ROS, and H2O2, as well as increased
phagocytosis were observed during the study of immunological alterations [119].
Several aromatic/heterocyclic sulfonamides and 5-mercapto-1,3,4-thiadiazoles were recently
investigated against L. donovani CAs. The sulfonamides were medium potency-weak inhibi‐
tors, but some heterocyclic thiols inhibited the enzyme with KIs in the range of 13.4–52 nM.
Microscopic studies revealed cell swelling and structural alterations on the flagellar pocket
such as presence of vacuoles. Autophagic vacuoles that cause intracellular damages and
parasite death, and accumulation of intracytoplasmic electron-dense granules were also
induced by the inhibitors. These result suggest that β-CA from Leishmania is a potential new
antileishmanial drug target [102].
7. Conclusions
Leishmaniasis is a neglected, potentially lethal infectious disease caused by parasites in the
genus Leishmania that affects many developing countries. Infection can lead to tegumentary or
visceral manifestations of the disease. The tegumentary form of leishmaniasis (TL) includes
cutaneous, mucocutaneous, and diffuse clinical manifestations, whereas visceral leishmaniasis
(VL), or Kala-azar, affects organs and internal tissues. The treatment of VL is challenging and
long. Treated patients need monitoring and hospitalization. Therapeutic problems include
toxicity and teratogenicity of the available drugs, and low response in human immu‐
nodeficiency virus (HIV)/Leishmania co-infections. In addition, drug resistance is increasing.
Moreover, leishmaniasis received little attention from governments and the pharmaceutical
industry until the last decade. The absence of either prophylactic or preventive vaccine
candidates makes it further difficult to control the disease.
The development of new parasite targets and synthetic drugs along with the research on
natural products represents a major strategy for the discovery of new compounds against
Leishmania sp.
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